Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation - A study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Gauthier, J.; Poiré, X.; Gac, A.-C.; Leclerc, M.; Guillaume, T.; Chalandon, Y.; Nguyen, S.; Forcade, E.; Régny, C.; Bay, J.-O.; Bazarbachi, A.; Rohrlich, P.-S.; Huynh, A.; Farhi, J.; Marchand, T.; Malfuson, J.-V.; Pilorge, S.; Labussière-Wallet, H.; Renard, C.; Fornecker, L.-M.; Detrait, M.; Duléry, R.; Delage, J.; Ménard, A.-L.; Charbonnier, A.; Nelken, B.; Jubert, C.; Suarez, F.; De La Tour, R. P.; Beguin, Yves; Schoemans, H.; Blaise, D.; Yakoub-Agha, I.

doi:10.1038/s41409-017-0018-z

Article (Scientific journals)

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation - A study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Gauthier, J.; Poiré, X.; Gac, A.-C. et al.

2018 • In Bone Marrow Transplantation, 53 (4), p. 400-409

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/232141

DOI
10.1038/s41409-017-0018-z

PubMed
29330405

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

402.pdf

Publisher postprint (932.61 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Article; HLA matching; Hodgkin disease

Abstract :

[en] The question of the best donor type between haploidentical (HAPLO) and matched-related donors (MRD) for patients with advanced HL receiving an allogeneic hematopoietic cell transplantation (allo-HCT) is still debated. Given the lack of data comparing these two types of donor in the setting of non-myeloablative (NMA) or reduced-intensity (RIC) allo-HCT, we performed a multicentre retrospective study using graft-vs.-host disease-free relapse-free survival (GRFS) as our primary endpoint. We analysed the data of 151 consecutive HL patients who underwent NMA or RIC allo-HCT from a HAPLO (N = 61) or MRD (N = 90) between January 2011 and January 2016. GRFS was defined as the probability of being alive without evidence of relapse, grade 3-4 acute GVHD or chronic GVHD. In multivariable analysis, MRD donors were independently associated with lower GRFS compared to HAPLO donors (HR = 2.95, P < 0.001). Disease status at transplant other than CR was also associated with lower GRFS in multivariable analysis (HR = 1.74, P = 0.01). In addition, the administration of ATG was independently linked to higher GRFS (HR = 0.52, P = 0.009). In summary, we observed significantly higher GRFS in HL patients receiving an allo-HCT using the HAPLO PT-Cy platform compared to MRD. © 2017 Macmillan Publishers Ltd., part of Springer Nature.

Disciplines :

Hematology

Author, co-author :

Gauthier, J.; Department of Hematology, CHRU Lille, Lille, France

Poiré, X.; Section of Haematology, Clinique Universitaire de St-Luc, Brussels, Belgium

Gac, A.-C.; Department of Haematology, Caen University Hospital France, Caen, France

Leclerc, M.; Department of Haematology, Henri-Mondor Hospital, APHP, Paris, France

Guillaume, T.; Department of Haematology, Nantes University Hospital, Nantes, France

Chalandon, Y.; Haematology Service Oncology Department, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland

Nguyen, S.; Department of Haematology, Pitié Salpêtrière Hospital, APHP, Paris, France

Forcade, E.; Department of Haematology and Cellular Therapy, University Hospital Bordeaux, Bordeaux, France

Régny, C.; Department of Haematology, Grenoble University Hospital, Grenoble, France

Bay, J.-O.; Department of Haematology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France

More authors (23 more)

Language :

English

Title :

Publication date :

2018

Journal title :

Bone Marrow Transplantation

ISSN :

0268-3369

eISSN :

1476-5365

Publisher :

Nature Publishing Group

Volume :

Issue :

Pages :

400-409

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 24 January 2019

Statistics

Number of views

385 (2 by ULiège)

Number of downloads

322 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, et al. Allogeneic transplantation improves the overall and progressionfree survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115:3671-7.
Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant. 2014;49:190-4.
Gayoso Balsalobre, Pascual Castilla-Llorente, López-Corral Kwon, et al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplant. 2016;51:1307-12.
Castagna Bramanti, Devillier Sarina, Crocchiolo Furst, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplant. 2017;52:683-88.
Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641-50.
Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1279-87.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-33.
Blaise D, Nguyen S, Bay JO, Chevallier P, Contentin N, Dhedin N, et al. [Allogeneic stem cell transplantation from an HLAhaploidentical related donor: SFGM-TC recommendations (Part 1)]. Pathol Biol. 2014;62:180-4.
Nguyen S, Chalandon Y, Lemarie C, Simon S, Masson D, Dhedin N, et al. [Haploidentical hematopoietic stem cell transplantation: guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer. 2016;103:S229-42.
Nguyen S, Blaise D, Bay JO, Chevallier P, Contentin N, Dhedin N, et al. [Allogeneic stem cell transplantation from an HLAhaploidentical related donor: SFGM-TC recommendations (part 2)]. Pathol Biol. 2014;62:185-9.
Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333-8.
Prentice RL, Kalbfleisch JD, Peterson JA, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541-54.
Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus hla-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016;34:3141-9. https://doi.org/10.1200/JCO.2015.66.3476.
Garciaz S, Castagna L, Bouabdallah R, Furst S, Bramanti S, Coso D, et al. Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transplant. 2015;50:880.
Kanakry C, Coffey D, Towlerton A, Vulic A, Storer B, Chou J, et al. Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. Jci Insight. 2016;1: e86252.
Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389-99.
Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD, et al. Identification and expansion of highly suppressive CD8 (+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood. 2012;119:5898-908.
Zheng J, Liu Y, Liu Y, Liu M, Xiang Z, Lam KT, et al. Human CD8+regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Sci Transl Med. 2013;5:168ra9.
Ganguly S, Ross D, Panoskaltsis-Mortari A, Kanakry C, Blazar B, Levy R, et al. Donor CD4+Foxp3+regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014;124:2131-41.
McCurdy S, Kasamon Y, Kanakry C, Bolaños-Meade J, Tsai H-L, Showel M, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2016;102:391-400.
Mielcarek M, Furlong T, O'Donnell P, Storer B, McCune J, Storb R, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127:1502-08.
Rashidi A, Slade M, DiPersio JF, Westervelt P, Vij R, Romee R. Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. Bone Marrow Transplant. 2016;51:1561-64.
Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino P, Bartolomeo Pdi, et al. Antithymocyte globulin for graft-versushost disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942-47.
Socié G, Schmoor C, Bethge W, Ottinger H, Stelljes M, Zander A, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117:6375-82.
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graftversus- host disease. New Engl J Med. 2016;374:43-53.